{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:28:13Z","timestamp":1765733293109,"version":"3.48.0"},"reference-count":26,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["272493"],"award-info":[{"award-number":["272493"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,9,13]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study was to investigate the use of, and predictors for, pharmaceutical anticancer treatment (PACT) towards the end of a patient\u2019s life in a country with a public healthcare system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective registry study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Secondary care in Norway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All Norwegian patients with cancer (International Classification of Diseases tenth revision (ICD-10) codes C00\u201399, D00\u201309, D37\u201348) in contact with a somatic hospital in Norway between 2009 and 2017 (N=420 655). Analyses were performed on a subsample of decedents with follow-back time of more than 1 year (2013\u20132017, N=52 496).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>N\/A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Proportion of patients receiving PACT during the last year and month of life. We calculated CIs with block bootstrapping, while predictors of PACT were estimated with logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>24.0% (95% CI 23.4% to 24.6%) of the patients received PACT during the last year of life and 3.2% (95% CI 3.0% to 3.5%) during their final month. The proportion during the last month was highest for multiple myeloma (12.7%) and breast cancer (6.5%) and lowest for urinary tract (1.1%) and prostate and kidney cancer (1.4%). Patients living in northern (OR 0.80, 95% CI 0.68 to 0.94) and western (OR 0.85, 95% CI 0.75 to 0.96) Norway had lower odds of PACT during the last month, while patients with myeloma (OR 3.0, 95% CI 2.5 to 3.7) and breast (OR 1.4, 95% CI 1.1 to 1.6) had higher odds. Kidney cancer (OR 0.25, 95% CI 0.2. to 0.4), urinary tract (OR 0.38, 95% CI 0.3 to 0.5) and prostate cancer (OR 0.4, 95% CI 0.3 to 0.5) were associated with lower probability of receiving PACT within the last month.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The proportion of patients receiving PACT in Norway is lower than in several other industrialised countries. Age, type of cancer and area of living are significant determinants of variation in PACT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-050564","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T13:24:50Z","timestamp":1632749090000},"page":"e050564","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0766-2870","authenticated-orcid":false,"given":"Christoffer","family":"Bugge","sequence":"first","affiliation":[{"name":"Department of Health Management and Health Economics, University of Oslo, Oslo, Norway"},{"name":"Oslo Economics AS, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein","family":"Kaasa","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik Magnus","family":"S\u00e6ther","sequence":"additional","affiliation":[{"name":"Oslo Economics AS, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Olav","family":"Melberg","sequence":"additional","affiliation":[{"name":"Department of Health Management and Health Economics, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivar","family":"Sonbo Kristiansen","sequence":"additional","affiliation":[{"name":"Department of Health Management and Health Economics, University of Oslo, Oslo, Norway"},{"name":"Oslo Economics AS, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"2025121409240946000_11.9.e050564.1","unstructured":"Cayne BS . The new lexicon Webster\u2019s dictionary of the English language: Outlet 1987."},{"key":"2025121409240946000_11.9.e050564.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2004.40134.x"},{"key":"2025121409240946000_11.9.e050564.3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/onco.13625","article-title":"Timing of palliative care referral before and after evidence from trials supporting early palliative care","volume":"26","author":"Hausner","year":"2021","journal-title":"Oncologist"},{"key":"2025121409240946000_11.9.e050564.4","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1200\/JCO.2018.36.15_suppl.3603","article-title":"Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): a pooled analysis of 28,636 patients (pts) in the ACCENT database","volume":"36","author":"Wagner","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025121409240946000_11.9.e050564.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000678"},{"key":"2025121409240946000_11.9.e050564.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0830"},{"key":"2025121409240946000_11.9.e050564.7","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2019.4064","article-title":"The Evolving Uses of \"Real-World\" Data","volume":"321","author":"Basch","year":"2019","journal-title":"JAMA"},{"key":"2025121409240946000_11.9.e050564.8","unstructured":"Ministry of Health and Care Services . White paper (Meld. St. 34 (2015\u20132016) on priority setting in the health service [in Norwegian]. Oslo Ministry of Health and Care Services; 2016."},{"key":"2025121409240946000_11.9.e050564.9","doi-asserted-by":"publisher","DOI":"10.1177\/0269216314533813"},{"key":"2025121409240946000_11.9.e050564.10","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamaoncol.2018.6196","article-title":"Association between reimbursement incentives and physician practice in oncology: a systematic review","volume":"5","author":"Mitchell","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025121409240946000_11.9.e050564.11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/annonc\/mdw654","article-title":"Use of chemotherapy near the end of life: what factors matter?","volume":"28","author":"Rochigneux","year":"2017","journal-title":"Ann Oncol"},{"key":"2025121409240946000_11.9.e050564.12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/0269216318786393","article-title":"Is specialized palliative cancer care associated with use of antineoplastic treatment at the end of life? a population-based cohort study","volume":"32","author":"Skov Benthien","year":"2018","journal-title":"Palliat Med"},{"key":"2025121409240946000_11.9.e050564.13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4045\/tidsskr.13.1417","article-title":"Norsk pasientregister \u2013 en viktig kilde for forskning","volume":"134","author":"Bakken","year":"2014","journal-title":"Tidsskriftet"},{"key":"2025121409240946000_11.9.e050564.14","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4045\/tidsskr.11.1099","article-title":"Comparison of data from the Norwegian patient register and the cancer registry of Norway","volume":"132","author":"Bakken","year":"2012","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2025121409240946000_11.9.e050564.15","unstructured":"Cancer Registry of Norway . Cancer in Norway 2017 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo Cancer Registry of Norway; 2018."},{"key":"2025121409240946000_11.9.e050564.16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1214\/aos\/1018031117","article-title":"Theoretical comparisons of block bootstrap methods","volume":"27","author":"Lahiri","year":"1999","journal-title":"The Annals of Statistics"},{"key":"2025121409240946000_11.9.e050564.17","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-019-0399-4"},{"key":"2025121409240946000_11.9.e050564.18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-8-200304150-00011"},{"key":"2025121409240946000_11.9.e050564.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.136"},{"key":"2025121409240946000_11.9.e050564.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8253"},{"key":"2025121409240946000_11.9.e050564.21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr416"},{"key":"2025121409240946000_11.9.e050564.22","doi-asserted-by":"publisher","DOI":"10.1159\/000112802"},{"key":"2025121409240946000_11.9.e050564.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.18603"},{"key":"2025121409240946000_11.9.e050564.24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-306","article-title":"Delivery of health care at the end of life in cancer patients of four Swiss cantons: a retrospective database study (SAKK 89\/09)","volume":"14","author":"Matter-Walstra","year":"2014","journal-title":"BMC Cancer"},{"key":"2025121409240946000_11.9.e050564.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.22.2765"},{"key":"2025121409240946000_11.9.e050564.26","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2012.000539"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-050564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:24:20Z","timestamp":1765733060000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-050564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,27]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bmjopen-2021-050564"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-050564","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}